Renin as a Prognostic and Predictive Biomarker in Sepsis: More Questions Than Answers?

Autor: See EJ; Department of Intensive Care, Royal Melbourne Hospital, Parkville, NSW, Australia.; Department of Critical Care, University of Melbourne, Parkville, NSW, Australia.; Department of Intensive Care, Austin Hospital, Heidelberg, VIC, Australia.; Department of Critical Care, Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, VIC, Australia.; Department of Medicine, Centre for Heart Lung Innovation, University of British Columbia and St Paul's Hospital, Vancouver, BC, Canada.; Department of Medicine, McGill University Health Centre and McGill University, Montreal, QC, Canada.; Division of Cardiology and Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, ON, Canada., Russell JA; Department of Medicine, Centre for Heart Lung Innovation, University of British Columbia and St Paul's Hospital, Vancouver, BC, Canada., Bellomo R; Department of Intensive Care, Royal Melbourne Hospital, Parkville, NSW, Australia.; Department of Critical Care, University of Melbourne, Parkville, NSW, Australia.; Department of Intensive Care, Austin Hospital, Heidelberg, VIC, Australia.; Department of Critical Care, Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, VIC, Australia.; Department of Medicine, Centre for Heart Lung Innovation, University of British Columbia and St Paul's Hospital, Vancouver, BC, Canada.; Department of Medicine, McGill University Health Centre and McGill University, Montreal, QC, Canada.; Division of Cardiology and Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, ON, Canada., Lawler PR; Department of Medicine, McGill University Health Centre and McGill University, Montreal, QC, Canada.; Division of Cardiology and Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, ON, Canada.
Jazyk: angličtina
Zdroj: Critical care medicine [Crit Care Med] 2024 Mar 01; Vol. 52 (3), pp. 509-512. Date of Electronic Publication: 2024 Feb 21.
DOI: 10.1097/CCM.0000000000006133
Abstrakt: Competing Interests: Dr. Russell’s institution received funding from the Canadian Institutes of Health Research and the St. Paul’s Foundation; they are the inventor of patents owned by the University of British Columbia that are related to: 1) the use of proprotein convertase subtilisin/kexin type 9 inhibitor(s) in sepsis, 2) the use of vasopressin in septic shock, and 3) a patent owned by Ferring for use of selepressin in septic shock; they disclosed they were a founder, director, and shareholder in Cyon Therapeutics Inc; they disclosed they are a shareholder in Molecular You Corp; they disclosed they are Senior Research Advisor of the British Columbia, Canada Post COVID—Interdisciplinary Clinical Care Network; they disclosed use of angiotensin receptor blockers. Dr. Bellomo received speaker fees from Paion and Viatris. Dr. Lawler is supported by the Fonds de Recherche du Quebec—Sante. The remaining authors have disclosed that they do not have any potential conflicts of interest.
Databáze: MEDLINE